Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment Article Swipe
Eugénie Rigault
,
Benjamin Lacas
,
Olivier Gléhen
,
Denis Smith
,
Eric Dupont-Bierre
,
Rosine Guimbaud
,
David Malka
,
Valérie Boige
,
Alina Fuerea
,
Jean‐Pierre Pignon
,
Michel Ducreux
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1016/j.ctarc.2022.100674
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1016/j.ctarc.2022.100674
IAH bevacizumab combined to systemic chemotherapy is feasible and safe in patients with unresectable isolated or dominant CRLM progressing after a first-line systemic treatment. Based on the low number of patients included in our study, our results suggest that this treatment does not increase dramatically the response rate versus an adapted systemic treatment. However, considering the safety data provided in this study, arterial infusion of bevacizumab in adjunction to chemotherapeutic agents could be evaluated in the future.
Related Topics
Concepts
Medicine
Bevacizumab
Irinotecan
Oxaliplatin
Clinical endpoint
Colorectal cancer
Internal medicine
Metastasis
Capecitabine
Chemotherapy
Population
Hepatic arterial infusion
Surgery
Gastroenterology
Oncology
Cancer
Randomized controlled trial
Environmental health
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.ctarc.2022.100674
- OA Status
- gold
- Cited By
- 5
- References
- 24
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4312141253
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4312141253Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.ctarc.2022.100674Digital Object Identifier
- Title
-
Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatmentWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-12-16Full publication date if available
- Authors
-
Eugénie Rigault, Benjamin Lacas, Olivier Gléhen, Denis Smith, Eric Dupont-Bierre, Rosine Guimbaud, David Malka, Valérie Boige, Alina Fuerea, Jean‐Pierre Pignon, Michel DucreuxList of authors in order
- Landing page
-
https://doi.org/10.1016/j.ctarc.2022.100674Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.ctarc.2022.100674Direct OA link when available
- Concepts
-
Medicine, Bevacizumab, Irinotecan, Oxaliplatin, Clinical endpoint, Colorectal cancer, Internal medicine, Metastasis, Capecitabine, Chemotherapy, Population, Hepatic arterial infusion, Surgery, Gastroenterology, Oncology, Cancer, Randomized controlled trial, Environmental healthTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
5Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2024: 3, 2023: 1Per-year citation counts (last 5 years)
- References (count)
-
24Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4312141253 |
|---|---|
| doi | https://doi.org/10.1016/j.ctarc.2022.100674 |
| ids.doi | https://doi.org/10.1016/j.ctarc.2022.100674 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/36565566 |
| ids.openalex | https://openalex.org/W4312141253 |
| fwci | 0.93882186 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000009 |
| mesh[1].descriptor_ui | D000971 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | adverse effects |
| mesh[1].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[2].qualifier_ui | Q000008 |
| mesh[2].descriptor_ui | D000068258 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | administration & dosage |
| mesh[2].descriptor_name | Bevacizumab |
| mesh[3].qualifier_ui | Q000473 |
| mesh[3].descriptor_ui | D015179 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | pathology |
| mesh[3].descriptor_name | Colorectal Neoplasms |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D006499 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Hepatic Artery |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D007261 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Infusions, Intra-Arterial |
| mesh[6].qualifier_ui | Q000188 |
| mesh[6].descriptor_ui | D008113 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | drug therapy |
| mesh[6].descriptor_name | Liver Neoplasms |
| mesh[7].qualifier_ui | Q000556 |
| mesh[7].descriptor_ui | D008113 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | secondary |
| mesh[7].descriptor_name | Liver Neoplasms |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D011446 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Prospective Studies |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D006801 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Humans |
| mesh[10].qualifier_ui | Q000009 |
| mesh[10].descriptor_ui | D000971 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | adverse effects |
| mesh[10].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[11].qualifier_ui | Q000008 |
| mesh[11].descriptor_ui | D000068258 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | administration & dosage |
| mesh[11].descriptor_name | Bevacizumab |
| mesh[12].qualifier_ui | Q000473 |
| mesh[12].descriptor_ui | D015179 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | pathology |
| mesh[12].descriptor_name | Colorectal Neoplasms |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D006499 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Hepatic Artery |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D007261 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Infusions, Intra-Arterial |
| mesh[15].qualifier_ui | Q000188 |
| mesh[15].descriptor_ui | D008113 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | drug therapy |
| mesh[15].descriptor_name | Liver Neoplasms |
| mesh[16].qualifier_ui | Q000556 |
| mesh[16].descriptor_ui | D008113 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | secondary |
| mesh[16].descriptor_name | Liver Neoplasms |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D011446 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Prospective Studies |
| type | article |
| title | Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment |
| biblio.issue | |
| biblio.volume | 34 |
| biblio.last_page | 100674 |
| biblio.first_page | 100674 |
| topics[0].id | https://openalex.org/T10073 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2721 |
| topics[0].subfield.display_name | Hepatology |
| topics[0].display_name | Hepatocellular Carcinoma Treatment and Prognosis |
| topics[1].id | https://openalex.org/T11067 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9997000098228455 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Colorectal Cancer Treatments and Studies |
| topics[2].id | https://openalex.org/T11364 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9991999864578247 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Cholangiocarcinoma and Gallbladder Cancer Studies |
| is_xpac | False |
| apc_list.value | 1650 |
| apc_list.currency | USD |
| apc_list.value_usd | 1650 |
| apc_paid.value | 1650 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 1650 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9291692972183228 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2777802072 |
| concepts[1].level | 3 |
| concepts[1].score | 0.9070351123809814 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q413299 |
| concepts[1].display_name | Bevacizumab |
| concepts[2].id | https://openalex.org/C2780259306 |
| concepts[2].level | 4 |
| concepts[2].score | 0.7484838962554932 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q412197 |
| concepts[2].display_name | Irinotecan |
| concepts[3].id | https://openalex.org/C2780962732 |
| concepts[3].level | 4 |
| concepts[3].score | 0.719733476638794 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q422327 |
| concepts[3].display_name | Oxaliplatin |
| concepts[4].id | https://openalex.org/C203092338 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6167801022529602 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1340863 |
| concepts[4].display_name | Clinical endpoint |
| concepts[5].id | https://openalex.org/C526805850 |
| concepts[5].level | 3 |
| concepts[5].score | 0.6137509942054749 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q188874 |
| concepts[5].display_name | Colorectal cancer |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5643735527992249 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C2779013556 |
| concepts[7].level | 3 |
| concepts[7].score | 0.5167362093925476 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q181876 |
| concepts[7].display_name | Metastasis |
| concepts[8].id | https://openalex.org/C2777909004 |
| concepts[8].level | 4 |
| concepts[8].score | 0.4985389709472656 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q420207 |
| concepts[8].display_name | Capecitabine |
| concepts[9].id | https://openalex.org/C2776694085 |
| concepts[9].level | 2 |
| concepts[9].score | 0.4928905963897705 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[9].display_name | Chemotherapy |
| concepts[10].id | https://openalex.org/C2908647359 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4691274166107178 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[10].display_name | Population |
| concepts[11].id | https://openalex.org/C2778405590 |
| concepts[11].level | 4 |
| concepts[11].score | 0.4584881663322449 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q5731662 |
| concepts[11].display_name | Hepatic arterial infusion |
| concepts[12].id | https://openalex.org/C141071460 |
| concepts[12].level | 1 |
| concepts[12].score | 0.4238497018814087 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[12].display_name | Surgery |
| concepts[13].id | https://openalex.org/C90924648 |
| concepts[13].level | 1 |
| concepts[13].score | 0.41041308641433716 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[13].display_name | Gastroenterology |
| concepts[14].id | https://openalex.org/C143998085 |
| concepts[14].level | 1 |
| concepts[14].score | 0.3733339309692383 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[14].display_name | Oncology |
| concepts[15].id | https://openalex.org/C121608353 |
| concepts[15].level | 2 |
| concepts[15].score | 0.33144405484199524 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[15].display_name | Cancer |
| concepts[16].id | https://openalex.org/C168563851 |
| concepts[16].level | 2 |
| concepts[16].score | 0.310752809047699 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[16].display_name | Randomized controlled trial |
| concepts[17].id | https://openalex.org/C99454951 |
| concepts[17].level | 1 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[17].display_name | Environmental health |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9291692972183228 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/bevacizumab |
| keywords[1].score | 0.9070351123809814 |
| keywords[1].display_name | Bevacizumab |
| keywords[2].id | https://openalex.org/keywords/irinotecan |
| keywords[2].score | 0.7484838962554932 |
| keywords[2].display_name | Irinotecan |
| keywords[3].id | https://openalex.org/keywords/oxaliplatin |
| keywords[3].score | 0.719733476638794 |
| keywords[3].display_name | Oxaliplatin |
| keywords[4].id | https://openalex.org/keywords/clinical-endpoint |
| keywords[4].score | 0.6167801022529602 |
| keywords[4].display_name | Clinical endpoint |
| keywords[5].id | https://openalex.org/keywords/colorectal-cancer |
| keywords[5].score | 0.6137509942054749 |
| keywords[5].display_name | Colorectal cancer |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.5643735527992249 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/metastasis |
| keywords[7].score | 0.5167362093925476 |
| keywords[7].display_name | Metastasis |
| keywords[8].id | https://openalex.org/keywords/capecitabine |
| keywords[8].score | 0.4985389709472656 |
| keywords[8].display_name | Capecitabine |
| keywords[9].id | https://openalex.org/keywords/chemotherapy |
| keywords[9].score | 0.4928905963897705 |
| keywords[9].display_name | Chemotherapy |
| keywords[10].id | https://openalex.org/keywords/population |
| keywords[10].score | 0.4691274166107178 |
| keywords[10].display_name | Population |
| keywords[11].id | https://openalex.org/keywords/hepatic-arterial-infusion |
| keywords[11].score | 0.4584881663322449 |
| keywords[11].display_name | Hepatic arterial infusion |
| keywords[12].id | https://openalex.org/keywords/surgery |
| keywords[12].score | 0.4238497018814087 |
| keywords[12].display_name | Surgery |
| keywords[13].id | https://openalex.org/keywords/gastroenterology |
| keywords[13].score | 0.41041308641433716 |
| keywords[13].display_name | Gastroenterology |
| keywords[14].id | https://openalex.org/keywords/oncology |
| keywords[14].score | 0.3733339309692383 |
| keywords[14].display_name | Oncology |
| keywords[15].id | https://openalex.org/keywords/cancer |
| keywords[15].score | 0.33144405484199524 |
| keywords[15].display_name | Cancer |
| keywords[16].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[16].score | 0.310752809047699 |
| keywords[16].display_name | Randomized controlled trial |
| language | en |
| locations[0].id | doi:10.1016/j.ctarc.2022.100674 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210186504 |
| locations[0].source.issn | 2468-2942 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2468-2942 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Cancer Treatment and Research Communications |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_lineage_names | Elsevier BV |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cancer Treatment and Research Communications |
| locations[0].landing_page_url | https://doi.org/10.1016/j.ctarc.2022.100674 |
| locations[1].id | pmid:36565566 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cancer treatment and research communications |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/36565566 |
| locations[2].id | pmh:oai:HAL:hal-04122484v1 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306402512 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | HAL (Le Centre pour la Communication Scientifique Directe) |
| locations[2].source.host_organization | https://openalex.org/I1294671590 |
| locations[2].source.host_organization_name | Centre National de la Recherche Scientifique |
| locations[2].source.host_organization_lineage | https://openalex.org/I1294671590 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Journal articles |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Cancer Treatment and Research Communications, 2023, 34, ⟨10.1016/j.ctarc.2022.100674⟩ |
| locations[2].landing_page_url | https://hal.science/hal-04122484 |
| locations[3].id | pmh:oai:doaj.org/article:c22bcb3444d34782a25dee5d64cfa6c8 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Cancer Treatment and Research Communications, Vol 34, Iss , Pp 100674- (2023) |
| locations[3].landing_page_url | https://doaj.org/article/c22bcb3444d34782a25dee5d64cfa6c8 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5001858805 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Eugénie Rigault |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[0].affiliations[0].raw_affiliation_string | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[0].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[0].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Institut Gustave Roussy |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Eugénie Rigault |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[1].author.id | https://openalex.org/A5015708695 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4416-5950 |
| authorships[1].author.display_name | Benjamin Lacas |
| authorships[1].countries | FR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210103698 |
| authorships[1].affiliations[0].raw_affiliation_string | CESP - Centre de recherche en épidémiologie et santé des populations (16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France - France) |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I2801843802 |
| authorships[1].affiliations[1].raw_affiliation_string | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[1].institutions[0].id | https://openalex.org/I4210103698 |
| authorships[1].institutions[0].ror | https://ror.org/01ed4t417 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I154526488, https://openalex.org/I195731000, https://openalex.org/I277688954, https://openalex.org/I277688954, https://openalex.org/I4210097159, https://openalex.org/I4210097159, https://openalex.org/I4210103698, https://openalex.org/I4210164847, https://openalex.org/I4413047524 |
| authorships[1].institutions[0].country_code | FR |
| authorships[1].institutions[0].display_name | Centre de recherche en Epidémiologie et Santé des Populations |
| authorships[1].institutions[1].id | https://openalex.org/I2801843802 |
| authorships[1].institutions[1].ror | https://ror.org/0321g0743 |
| authorships[1].institutions[1].type | facility |
| authorships[1].institutions[1].lineage | https://openalex.org/I2801843802 |
| authorships[1].institutions[1].country_code | FR |
| authorships[1].institutions[1].display_name | Institut Gustave Roussy |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Benjamin Lacas |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | CESP - Centre de recherche en épidémiologie et santé des populations (16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France - France), IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[2].author.id | https://openalex.org/A5031036666 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-2802-4974 |
| authorships[2].author.display_name | Olivier Gléhen |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I100532134 |
| authorships[2].affiliations[0].raw_affiliation_string | Université de Lyon (92 rue Pasteur - CS 30122, 69361 Lyon Cedex 07 - France) |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I4210100596 |
| authorships[2].affiliations[1].raw_affiliation_string | HCL - Hospices Civils de Lyon (3 Quai des Célestins 69002 Lyon - France) |
| authorships[2].institutions[0].id | https://openalex.org/I4210100596 |
| authorships[2].institutions[0].ror | https://ror.org/01502ca60 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210100596 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Hospices Civils de Lyon |
| authorships[2].institutions[1].id | https://openalex.org/I100532134 |
| authorships[2].institutions[1].ror | https://ror.org/029brtt94 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I100532134, https://openalex.org/I203339264 |
| authorships[2].institutions[1].country_code | FR |
| authorships[2].institutions[1].display_name | Université Claude Bernard Lyon 1 |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Olivier Glehen |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | HCL - Hospices Civils de Lyon (3 Quai des Célestins 69002 Lyon - France), Université de Lyon (92 rue Pasteur - CS 30122, 69361 Lyon Cedex 07 - France) |
| authorships[3].author.id | https://openalex.org/A5077844357 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-3155-6709 |
| authorships[3].author.display_name | Denis Smith |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210120975 |
| authorships[3].affiliations[0].raw_affiliation_string | Hôpital Haut-Lévêque [CHU Bordeaux] (France) |
| authorships[3].institutions[0].id | https://openalex.org/I4210120975 |
| authorships[3].institutions[0].ror | https://ror.org/02bf3a828 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I3018323443, https://openalex.org/I4210120975 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Hôpital Cardiologique du Haut-Lévêque |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Denis Smith |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Hôpital Haut-Lévêque [CHU Bordeaux] (France) |
| authorships[4].author.id | https://openalex.org/A5052277414 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Eric Dupont-Bierre |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210124628 |
| authorships[4].affiliations[0].raw_affiliation_string | Hôpital Saint-Gregoire, France |
| authorships[4].institutions[0].id | https://openalex.org/I4210124628 |
| authorships[4].institutions[0].ror | https://ror.org/02byms354 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210124628 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Centre Hospitalier privé Saint Grégoire |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Eric Dupont-Bierre |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Hôpital Saint-Gregoire, France |
| authorships[5].author.id | https://openalex.org/A5091297068 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-8344-1762 |
| authorships[5].author.display_name | Rosine Guimbaud |
| authorships[5].countries | FR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I17866349 |
| authorships[5].affiliations[0].raw_affiliation_string | UT - Université de Toulouse (41 Allée Jules Guesde, 31000 Toulouse - France) |
| authorships[5].institutions[0].id | https://openalex.org/I17866349 |
| authorships[5].institutions[0].ror | https://ror.org/004raaa70 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I17866349 |
| authorships[5].institutions[0].country_code | FR |
| authorships[5].institutions[0].display_name | Université Fédérale de Toulouse Midi-Pyrénées |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Rosine Guimbaud |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | UT - Université de Toulouse (41 Allée Jules Guesde, 31000 Toulouse - France) |
| authorships[6].author.id | https://openalex.org/A5017132355 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-7664-0130 |
| authorships[6].author.display_name | David Malka |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[6].affiliations[0].raw_affiliation_string | TCD - Dynamique des cellules tumorales (Institut Gustave Roussy, 39 Rue Camille Desmoulins 94800, Villejuif - France) |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I2801843802 |
| authorships[6].affiliations[1].raw_affiliation_string | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[6].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[6].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[6].institutions[0].type | facility |
| authorships[6].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Institut Gustave Roussy |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | David Malka |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France), TCD - Dynamique des cellules tumorales (Institut Gustave Roussy, 39 Rue Camille Desmoulins 94800, Villejuif - France) |
| authorships[7].author.id | https://openalex.org/A5041492973 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-7817-4663 |
| authorships[7].author.display_name | Valérie Boige |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[7].affiliations[0].raw_affiliation_string | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[7].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[7].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[7].institutions[0].type | facility |
| authorships[7].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Institut Gustave Roussy |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Valérie Boige |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[8].author.id | https://openalex.org/A5056556465 |
| authorships[8].author.orcid | https://orcid.org/0009-0002-7074-0189 |
| authorships[8].author.display_name | Alina Fuerea |
| authorships[8].countries | FR |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[8].affiliations[0].raw_affiliation_string | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[8].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[8].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[8].institutions[0].type | facility |
| authorships[8].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[8].institutions[0].country_code | FR |
| authorships[8].institutions[0].display_name | Institut Gustave Roussy |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Alina Fuerea |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[9].author.id | https://openalex.org/A5043053032 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-2047-1582 |
| authorships[9].author.display_name | Jean‐Pierre Pignon |
| authorships[9].countries | FR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[9].affiliations[0].raw_affiliation_string | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[9].affiliations[1].institution_ids | https://openalex.org/I4210103698 |
| authorships[9].affiliations[1].raw_affiliation_string | CESP - Centre de recherche en épidémiologie et santé des populations (16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France - France) |
| authorships[9].institutions[0].id | https://openalex.org/I4210103698 |
| authorships[9].institutions[0].ror | https://ror.org/01ed4t417 |
| authorships[9].institutions[0].type | facility |
| authorships[9].institutions[0].lineage | https://openalex.org/I154526488, https://openalex.org/I195731000, https://openalex.org/I277688954, https://openalex.org/I277688954, https://openalex.org/I4210097159, https://openalex.org/I4210097159, https://openalex.org/I4210103698, https://openalex.org/I4210164847, https://openalex.org/I4413047524 |
| authorships[9].institutions[0].country_code | FR |
| authorships[9].institutions[0].display_name | Centre de recherche en Epidémiologie et Santé des Populations |
| authorships[9].institutions[1].id | https://openalex.org/I2801843802 |
| authorships[9].institutions[1].ror | https://ror.org/0321g0743 |
| authorships[9].institutions[1].type | facility |
| authorships[9].institutions[1].lineage | https://openalex.org/I2801843802 |
| authorships[9].institutions[1].country_code | FR |
| authorships[9].institutions[1].display_name | Institut Gustave Roussy |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Jean-Pierre Pignon |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | CESP - Centre de recherche en épidémiologie et santé des populations (16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France - France), IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[10].author.id | https://openalex.org/A5085121407 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-8649-7449 |
| authorships[10].author.display_name | Michel Ducreux |
| authorships[10].countries | FR |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[10].affiliations[0].raw_affiliation_string | TCD - Dynamique des cellules tumorales (Institut Gustave Roussy, 39 Rue Camille Desmoulins 94800, Villejuif - France) |
| authorships[10].affiliations[1].institution_ids | https://openalex.org/I2801843802 |
| authorships[10].affiliations[1].raw_affiliation_string | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France) |
| authorships[10].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[10].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[10].institutions[0].country_code | FR |
| authorships[10].institutions[0].display_name | Institut Gustave Roussy |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | Michel Ducreux |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France), TCD - Dynamique des cellules tumorales (Institut Gustave Roussy, 39 Rue Camille Desmoulins 94800, Villejuif - France) |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.ctarc.2022.100674 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10073 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2721 |
| primary_topic.subfield.display_name | Hepatology |
| primary_topic.display_name | Hepatocellular Carcinoma Treatment and Prognosis |
| related_works | https://openalex.org/W1520918055, https://openalex.org/W2377024980, https://openalex.org/W2361525411, https://openalex.org/W1988868424, https://openalex.org/W2799922918, https://openalex.org/W2373559083, https://openalex.org/W2621401569, https://openalex.org/W2378173381, https://openalex.org/W2356910782, https://openalex.org/W2418260427 |
| cited_by_count | 5 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1016/j.ctarc.2022.100674 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210186504 |
| best_oa_location.source.issn | 2468-2942 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2468-2942 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Cancer Treatment and Research Communications |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_lineage_names | Elsevier BV |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cancer Treatment and Research Communications |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.ctarc.2022.100674 |
| primary_location.id | doi:10.1016/j.ctarc.2022.100674 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210186504 |
| primary_location.source.issn | 2468-2942 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2468-2942 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Cancer Treatment and Research Communications |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_lineage_names | Elsevier BV |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cancer Treatment and Research Communications |
| primary_location.landing_page_url | https://doi.org/10.1016/j.ctarc.2022.100674 |
| publication_date | 2022-12-16 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W2783686102, https://openalex.org/W6688848551, https://openalex.org/W2005348280, https://openalex.org/W2712978371, https://openalex.org/W2007615142, https://openalex.org/W1835268604, https://openalex.org/W2087923534, https://openalex.org/W2468837473, https://openalex.org/W2104614485, https://openalex.org/W2094313851, https://openalex.org/W2098444281, https://openalex.org/W2157769714, https://openalex.org/W2143743735, https://openalex.org/W1968620853, https://openalex.org/W2125447919, https://openalex.org/W2160373161, https://openalex.org/W2081238655, https://openalex.org/W2158065302, https://openalex.org/W2052779140, https://openalex.org/W2121847974, https://openalex.org/W2221252789, https://openalex.org/W2174652897, https://openalex.org/W2014538139, https://openalex.org/W2212365310 |
| referenced_works_count | 24 |
| abstract_inverted_index.a | 20 |
| abstract_inverted_index.an | 49 |
| abstract_inverted_index.be | 72 |
| abstract_inverted_index.in | 10, 32, 59, 66, 74 |
| abstract_inverted_index.is | 6 |
| abstract_inverted_index.of | 29, 64 |
| abstract_inverted_index.on | 25 |
| abstract_inverted_index.or | 15 |
| abstract_inverted_index.to | 3, 68 |
| abstract_inverted_index.IAH | 0 |
| abstract_inverted_index.and | 8 |
| abstract_inverted_index.low | 27 |
| abstract_inverted_index.not | 42 |
| abstract_inverted_index.our | 33, 35 |
| abstract_inverted_index.the | 26, 45, 55, 75 |
| abstract_inverted_index.CRLM | 17 |
| abstract_inverted_index.data | 57 |
| abstract_inverted_index.does | 41 |
| abstract_inverted_index.rate | 47 |
| abstract_inverted_index.safe | 9 |
| abstract_inverted_index.that | 38 |
| abstract_inverted_index.this | 39, 60 |
| abstract_inverted_index.with | 12 |
| abstract_inverted_index.Based | 24 |
| abstract_inverted_index.after | 19 |
| abstract_inverted_index.could | 71 |
| abstract_inverted_index.agents | 70 |
| abstract_inverted_index.number | 28 |
| abstract_inverted_index.safety | 56 |
| abstract_inverted_index.study, | 34, 61 |
| abstract_inverted_index.versus | 48 |
| abstract_inverted_index.adapted | 50 |
| abstract_inverted_index.future. | 76 |
| abstract_inverted_index.results | 36 |
| abstract_inverted_index.suggest | 37 |
| abstract_inverted_index.However, | 53 |
| abstract_inverted_index.arterial | 62 |
| abstract_inverted_index.combined | 2 |
| abstract_inverted_index.dominant | 16 |
| abstract_inverted_index.feasible | 7 |
| abstract_inverted_index.included | 31 |
| abstract_inverted_index.increase | 43 |
| abstract_inverted_index.infusion | 63 |
| abstract_inverted_index.isolated | 14 |
| abstract_inverted_index.patients | 11, 30 |
| abstract_inverted_index.provided | 58 |
| abstract_inverted_index.response | 46 |
| abstract_inverted_index.systemic | 4, 22, 51 |
| abstract_inverted_index.evaluated | 73 |
| abstract_inverted_index.treatment | 40 |
| abstract_inverted_index.adjunction | 67 |
| abstract_inverted_index.first-line | 21 |
| abstract_inverted_index.treatment. | 23, 52 |
| abstract_inverted_index.bevacizumab | 1, 65 |
| abstract_inverted_index.considering | 54 |
| abstract_inverted_index.progressing | 18 |
| abstract_inverted_index.chemotherapy | 5 |
| abstract_inverted_index.dramatically | 44 |
| abstract_inverted_index.unresectable | 13 |
| abstract_inverted_index.chemotherapeutic | 69 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 89 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 11 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.5400000214576721 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.70720312 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |